Compare Deere & Company (DE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Recursion Pharmaceuticals Inc — how do they compare? Deere & Company trades at $652.58 (market cap $177.11B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B). The key difference: Deere & Company is far larger — about 76.7× Recursion Pharmaceuticals Inc's market cap, and Deere & Company pays a 0.99% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| DE | RXRX | |
|---|---|---|
Market Cap | $177.11B | $2.31B |
Volume | 1,206,308 | 40,478,768 |
Sector | Industrials | Health |
52-Week High | $709.48 | $6.79 |
52-Week Low | $439.11 | $2.84 |
Typical Hold Time | 75 Days | 22 Days |
Enterprise Value | $231.01B | $1.83B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $652.58, down 4.42% today, showing bearish technical signals with support at $643 and resistance at $658. The company maintains strong profitability with a 10.39% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Deere's AI initiatives and institutional buying interest, though revenue has declined from 2023 peaks.
Deere presents a mixed outlook with solid fundamentals and analyst support (43.48% buy rating, $731.20 target) but faces agricultural cycle headwinds and competitive pressures. The stock offers potential upside from AI-driven farming solutions but risks include cyclical demand volatility and high debt levels at 60.31% of assets.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
